Tiffany Patterson, Nicolas Van Mieghem, and Philippe Généreux reveal the hottest emerging TAVI indications for 2025 in this #europcr 2025 discussion.
They review key trials on asymptomatic severe aortic stenosis—RECOVERY, AVATAR, ONLY TAVR, and EVoLVeD—which show early TAVI or surgery reduces hospitalisations for heart failure and suggests lower mortality and stroke compared to clinical surveillance.
The discussion then moves to symptomatic moderate aortic stenosis, highlighting the recent TAVR UNLOAD study in heart failure patients with reduced ejection fraction.
They also touch on the PROGRESS and EXPAND II trials, and share early insights on new devices for aortic regurgitation, now entering randomised comparisons with surgery.
Listen now to stay ahead on the expanding role of TAVI.
Hosted on Acast. See acast.com/privacy for more information.
